Related Experiment Video

Updated: Jun 28, 2025

Exploring the Arginine Methylome by Nuclear Magnetic Resonance Spectroscopy
07:02

Exploring the Arginine Methylome by Nuclear Magnetic Resonance Spectroscopy

Published on: December 16, 2021

1.4K

Protein Arginine Methyltransferases in Pancreatic Ductal Adenocarcinoma: New Molecular Targets for Therapy

Kritisha Bhandari1, Wei-Qun Ding1

  • 1Department of Pathology, University of Oklahoma Health Sciences Center, BMSB401A, 940 Stanton L. Young Blvd., Oklahoma City, OK 73104, USA.

International Journal of Molecular Sciences
|April 13, 2024
PubMed

Insights

Protein arginine methyltransferases (PRMTs) are overexpressed in pancreatic cancer, promoting tumor growth and resistance to chemotherapy. Targeting these enzymes offers a promising new therapeutic strategy for pancreatic ductal adenocarcinoma (PDAC).

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis due to limited effective treatments and late detection.
  • Current immunotherapies and targeted treatments for PDAC show unsatisfactory outcomes, necessitating novel therapeutic approaches.
  • Altered expression of protein arginine methyltransferases (PRMTs) is a newly identified molecular characteristic of PDAC.

Purpose of the Study:

  • To review the pathological roles of PRMTs in pancreatic ductal adenocarcinoma.
  • To explore the potential of PRMTs as novel therapeutic targets for PDAC treatment.

Main Methods:

  • Literature review of studies investigating PRMTs in PDAC.
  • Analysis of the molecular mechanisms by which PRMTs influence PDAC progression and chemo-resistance.
  • Examination of the clinical trial status of small-molecule PRMT inhibitors.

Main Results:

  • PRMTs are enzymes that methylate arginine residues, regulating cellular functions.
  • Overexpression of certain PRMTs in PDAC contributes to tumor progression, chemo-resistance, and epithelial-mesenchymal transition (EMT).
  • PRMTs impact gene transcription, cellular metabolism, and RNA processing in PDAC.

Conclusions:

  • PRMTs play significant pathological roles in pancreatic ductal adenocarcinoma.
  • Small-molecule inhibitors targeting PRMTs are under clinical investigation and represent a potential new class of anti-cancer drugs for PDAC.
Keywords:
arginine methylationmolecular targetspancreatic ductal adenocarcinoma (PDAC)protein arginine methyltransferases (PRMTs)

More Related Videos

Quantitative Methods to Study Protein Arginine Methyltransferase 1-9 Activity in Cells08:11

Quantitative Methods to Study Protein Arginine Methyltransferase 1-9 Activity in Cells

Published on: August 7, 2021

4.1K
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

790

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.5K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K